Business Case

Glaucoma Portfolio Optimization for a Large Pharmaceutical Company to Unlock Brand Synergies After Recent Acquisitions

A large pharmaceutical company recently acquired several potential glaucoma treatments and sought LSC’s guidance to help prioritize the bulging portfolio. LSC worked with our client to identify key prioritization metrics and subsequently conducted analysis resulting in the identification of four brands that were potentially highly synergistic. LSC worked to characterize the potential synergies for the client, including development timing, clinical applications, and physician targeting, ultimately resulting in a successful integration of the acquired portfolio.